pyrroles has been researched along with methotrexate in 128 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.56) | 18.7374 |
| 1990's | 3 (2.34) | 18.2507 |
| 2000's | 6 (4.69) | 29.6817 |
| 2010's | 99 (77.34) | 24.3611 |
| 2020's | 18 (14.06) | 2.80 |
| Authors | Studies |
|---|---|
| Muzik, H; Paterson, AR; Warnick, CT | 1 |
| Swanbeck, G | 1 |
| Clark, DE; Frenkel, D; Li, J; Murray, CW; Robson, B; Waszkowycz, B; Westhead, DR | 1 |
| Ichikawa, M; Matsuyama, K; Nakaboh, Y; Nakashima, M; Satoh, S; Yano, T | 1 |
| DiMartino, M; Nambi, P; Patil, A; Wolff, C | 1 |
| Akimoto, H; Itoh, F; Ootsu, K; Yoshida, S; Yoshioka, Y; Yukishige, K | 1 |
| Liu, B; Taylor, EC | 1 |
| Capell, HA; Ford, I; Hampson, R; Madhok, R; McCarey, DW; McInnes, IB; Sattar, N; Scherbakov, O | 1 |
| Fabian, V; Knezevic, W; Mastaglia, FL; Needham, M; Panegyres, P; Zilko, P | 1 |
| Chen, ZS; Dai, CL; Fu, LW; Liang, YJ; Tiwari, AK; Tong, XZ; Wang, F; Wang, YS; Yan, YY | 1 |
| Chow, V; Cohen, S; Labadie, RR; Wilkinson, B; Zwillich, SH | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Kremer, J; Krishnaswami, S; Riese, RJ | 1 |
| El-Barbary, AM; Hamouda, HE; Hussein, MS; Ismail, RG; Rageh, EM; Wagih, AA | 1 |
| Nakamura, H; Suzuki, M; Tanaka, Y; Toyoizumi, S; Zwillich, SH | 1 |
| Connell, CA; Cutolo, M; Fleischmann, R; Genovese, MC; Gruben, D; Kanik, KS; Krishnaswami, S; Lee, EB; Sadis, S; Wallenstein, G; Wilkinson, BE; Zwillich, SH | 1 |
| Cohen, S; Connell, CA; French, JL; Gomez-Reino, J; Gruben, D; Kanik, KS; Kremer, JM; Krishnaswami, S; Pascual-Ramos, V; Wallenstein, G; Wilkinson, BE; Zwillich, SH | 1 |
| Tanaka, Y | 2 |
| Leonardi, CL | 1 |
| Bradley, JD; Cohen, S; Fleischmann, R; Forejtova, S; García Meijide, JA; Gruben, D; Koncz, T; Krishnaswami, S; Lee, EB; van Vollenhoven, RF; Wagner, S; Wallenstein, GV; Wilkinson, B; Zwillich, SH | 1 |
| Miossec, P | 1 |
| Benda, B; Blanco, R; Bradley, J; Burmester, GR; Charles-Schoeman, C; Gruben, D; Koncz, T; Krishnaswami, S; Mebus, C; Soma, K; Wallenstein, G; Wollenhaupt, J; Zerbini, C; Zwillich, SH | 1 |
| Benda, B; Bradley, JD; Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Krishnaswami, S; Nash, P; Song, YW; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Wyman, BT; Zerbini, C; Zwillich, SH | 1 |
| Flores, RM; Kanth, R; Shah, MS | 1 |
| Abdel-Rahman, MN; El Rashidy, MA; El-Sisi, Ael-D; Ezzat, NM; Haleem, MS; Kabel, AM | 1 |
| Ferraccioli, G; Gremese, E | 1 |
| Benda, B; Bradley, J; Burmester, GR; Gruben, D; Mebus, C | 1 |
| Bradley, J; Fleischmann, R; Genovese, M; Gruben, D; Hall, S; Isaacs, JD; Koncz, T; Kremer, J; Krishnaswami, S; Li, ZG; Martin-Mola, E; Riese, R; Wallenstein, G; Zwillich, SH | 1 |
| Buch, MH; Gaujoux-Viala, C; Gossec, L; Landewé, R; Nam, J; Ramiro, S; Smolen, JS | 1 |
| Izumi, M; Izumi, Y; Jiuchi, Y; Kawahara, C; Kawakami, A; Kozuru, H; Migita, K; Motokawa, S; Nakamura, M; Nakamura, T; Sakai, T | 1 |
| Minota, S | 1 |
| Bradley, JD; Fleischmann, R; Gruben, D; Hall, S; Koncz, T; Krishnaswami, S; Lee, EB; van Vollenhoven, RF; Wallenstein, GV; Wilkinson, B; Zang, C; Zwillich, SH | 1 |
| Onuora, S | 2 |
| Benda, B; Cohen, S; Gomez-Reino, JJ; Krishnaswami, S; Kwok, K; Nduaka, CI; Radominski, SC; Riese, R; Soma, K; Valdez, H; Wang, L; Wood, SP | 1 |
| Kalra, S; Kaur, K; Kaushal, S | 1 |
| Burmester, GR; Gruben, D; Mebus, CA; Strand, V; Wallenstein, GV; Zerbini, CA; Zwillich, SH | 1 |
| Bae, SC; Lee, YH; Song, GG | 2 |
| Krishnaswami, S; van Vollenhoven, RF; Wilkinson, B | 1 |
| Sexton, D | 1 |
| Chen, J; Xu, A; Yuan, K | 1 |
| Dhiman, V; Dixit, A; Giri, K; Mullangi, R; Sharma, K; Zainuddin, M | 1 |
| Boyle, DL; Bradley, J; Firestein, GS; Hodge, J; Kaplan, I; Kavanaugh, A; Krishnaswami, S; Luo, Z; Mandel, D; Mease, P; Rosengren, S; Shurmur, R; Singhal, AK; Soma, K; Wei, N | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Tanaka, Y; Zwillich, SH | 1 |
| Bingham, CO; Fan, H; Gomez-Reino, J; Hodge, J; Hrycaj, P; Lee, EB; Mebus, C; Neal, J; Racewicz, A; Silverfield, J; Soma, K; Wang, T; Wilkinson, B; Winthrop, KL | 1 |
| Bananis, E; Burmester, G; Charles-Schoeman, C; Fleischmann, R; Hendrikx, T; Kwok, K; Nash, P; Soma, K; Zerbini, CA | 1 |
| Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R | 1 |
| Hirose, T; Morishima, Y; Sugiyama, N; Takeuchi, T; Tanaka, Y; Toyoizumi, S; Yamanaka, H; Yuasa, H; Zwillich, S | 1 |
| Fleischmann, R; Gruben, D; Koncz, T; Lee, EB; Strand, V; van Vollenhoven, RF; Wallenstein, G; Wilkinson, B; Zwillich, SH | 1 |
| Bowes, MA; Bradley, JD; Conaghan, PG; Fuerst, T; Hrycaj, P; Irazoque-Palazuelos, F; Soma, K; Soto-Raices, O; van der Heijde, D; Wilkinson, B; Wu, C; Wyman, BT; Xie, Z; Zhang, R; Østergaard, M | 1 |
| Candilera, V; De Iudicibus, S; Decorti, G; Loganes, C; Paron, G; Piscianz, E; Tommasini, A; Valencic, E | 1 |
| Christensen, R; Hossain, A; Kotb, A; Maxwell, LJ; Mudano, AS; Shah, NP; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Chen, Y; Clowse, ME; Feldman, SR; Frazier, D; Geier, J; Isaacs, JD; Kimball, AB; Marren, A; Proulx, J; Strand, V; Warren, RB; Xibillé, D | 1 |
| Kawahito, Y | 1 |
| Christopher-Stine, L; Paik, JJ | 1 |
| Bananis, E; Connell, CA; Fleischmann, R; Hwang, LJ; Mease, PJ; Schwartzman, S; Soma, K; Takiya, L | 1 |
| Hossain, A; Mudano, AS; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Braun, J | 1 |
| Jansen, JP; Smiechowski, B; Spurden, D; Vieira, MC; Wallenstein, GV; Zwillich, SH | 1 |
| Friedman, MA; Winthrop, KL | 1 |
| Buchbinder, R; Hossain, A; Lopez-Olivo, MA; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Passeron, T | 1 |
| Bijlsma, J; Burmester, G; Chatzidionysiou, K; Dougados, M; Emamikia, S; Landewé, R; Nam, J; Ramiro, S; Scholte, M; Smolen, J; van der Heijde, D; van Vollenhoven, R | 1 |
| Handa, H; Hosogai, M; Kishi, S; Mitsui, T; Ogawa, Y; Todokoro, D; Yanagisawa, K; Yokohama, A | 1 |
| Amano, W; Hayashi, M; Kakimoto, K; Katsuda, Y; Kimoto, Y; Konishi, N; Shinozaki, Y; Taniai-Riya, E; Tanimoto, A; Toyoda, K; Yamamoto, Y | 1 |
| Kosinski, M; Mebus, CA; Rendas-Baum, R; Singh, A; Wallenstein, GV; Wilkinson, BE | 1 |
| Amital, H; Gertel, S; Karmon, G; Mahagna, H; Watad, A | 1 |
| Amrouche, K; Jamin, C | 1 |
| Buchbinder, R; Hossain, A; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| DeMasi, R; Fleischmann, R; Hall, S; Kivitz, AJ; Krishnaswami, S; Luo, Z; Menon, S; Mojcik, C; Moots, RJ; Mysler, E; Smolen, JS; Soma, K; Takiya, L; Tatulych, S; Zhang, R | 1 |
| Fleischmann, R | 1 |
| Biswas, P; Choy, EH; Hodge, JA; Mojcik, CF; Nduaka, CI; Needle, E; Passador, S; Rigby, WF; Soma, K; Winthrop, KL; Wouters, AG | 1 |
| Bananis, E; Chen, C; Curtis, JR; Fan, H; Hirose, T; Lindsey, S; Mendelsohn, AM; Nduaka, CI; Tanaka, Y; Valdez, H; Wang, L; Winthrop, KL; Yamaoka, K | 1 |
| Amano, K; Hatta, K; Kanazawa, T; Kume, K; Kuwaba, N; Ohta, H; Yamada, S | 1 |
| Dhillon, S | 1 |
| Bananis, E; Burmester, GR; Charles-Schoeman, C; Connell, CA; Fan, H; Fleischmann, R; Kwok, K; Nash, P; van der Heijde, D; Zerbini, CAF | 1 |
| Mori, S; Ueki, Y; Yoshitama, T | 1 |
| Contreras-Yáñez, I; Ortiz-Haro, AB; Pascual-Ramos, V; Pérez-Román, DI; Ruiz-Medrano, E | 1 |
| Lacour, JP | 1 |
| Bermejo, I; Martyn-St James, M; Ren, S; Scott, DL; Stevenson, M; Uttley, L; Wong, R; Young, A | 1 |
| Abrahamowicz, M; Bernatsky, S; Curtis, JR; Guerra, SF; Machado, MAÁ; Moura, CS | 1 |
| Bananis, E; Bergman, MJ; Dikranian, A; Lee, EB; Strand, V; Takiya, L; Wilkinson, B; Yazici, Y; Zang, C | 1 |
| Bodycombe, D; Curtis, JR; Dyagilev, K; Kan, HJ; Kharrazi, H; Molta, CT; Saria, S; Schulam, P | 1 |
| Cho, H; Choy, EH; Hashizume, M; John, MR; O'Mahony, A | 1 |
| Bourret, JA; Claxton, L; Gerber, RA; Soonasra, A; Taylor, M | 1 |
| Hao, W; Li, C; Luo, Y; Yang, Q; Zhang, W; Zhao, Y | 1 |
| Akylbekova, EL; Brenol, CV; de Leon, DP; García, EG; Lomonte, ABV; Marcolino, FMD; Radominski, SC; Rojo, R; Zerbini, CAF | 1 |
| Bananis, E; Cohen, S; Connell, CA; Fan, H; Fleischmann, R; Haraoui, B; Kaine, J; Keystone, E; Kivitz, AJ; Takiya, L; van Vollenhoven, RF | 1 |
| Bernatsky, S; Chen, L; Curtis, JR; Winthrop, K; Xie, F; Yang, S; Yun, H | 1 |
| Azami, A; Hamidi, S; Mehdizadeh Aghdam, E | 1 |
| Cacciapaglia, F; Fornaro, M; Iannone, F; Lopalco, G; Venerito, V | 1 |
| Bertolo, MB; Brenol, CV; Castelar Pinheiro, GDR; Cruz, BA; de Albuquerque, CP; de Freitas, MVC; Duarte, ALBP; Giorgi, RDN; Gomides, APM; Kakehasi, AM; Laurindo, IMM; Louzada-Júnior, P; Mota, LMHD; Pereira, IA; Ubirajara Silva de Souza, MPG; Xavier, RM | 1 |
| Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Nash, P; Song, YW; Strand, V; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Zerbini, CAF | 1 |
| Dressler, C; Eisert, L; Nast, A; Pham, PA; Werner, RN | 1 |
| Taylor, PC | 1 |
| Deeks, ED; Paik, J | 1 |
| Yamaoka, K | 1 |
| Chen, CI; Fournier, M; Gal, P; Kiss, Z; Kuznik, A; Michaud, K; Muszbek, N; Proudfoot, C | 1 |
| Feng, Q; Guo, M; Qiu, Q; Tan, X | 1 |
| Abud-Mendoza, C; Calabrese, LH; Fleischmann, R; Iikuni, N; Lee, SH; Lindsey, SM; Luo, Z; Soma, K; Takiya, L; Tatulych, S | 1 |
| Choi, SJ; Lee, YH; Song, GG | 1 |
| Anderson, PO | 1 |
| Buchmann, J; Calderón, M; Laufer, J; Molina, M; Theune, LE; Wedepohl, S | 1 |
| Krüger, K | 1 |
| Andrews, J; Bowes, MA; Chapman, D; Conaghan, PG; Guillard, G; Koenig, A; Stein, A; Troum, O; Wilkinson, B; Xie, Z; Østergaard, M | 1 |
| DeMasi, R; Fleischmann, R; Gruben, D; Iikuni, N; Moots, RJ; Mysler, E; Smolen, JS; Soma, K; Strand, V; Wallenstein, GV | 1 |
| Lee, YH; Song, GG | 3 |
| Estevez, AJ; Papagno, MJ; Vinicki, JP | 1 |
| Betts, KA; Du, EX; Pope, J; Qi, CZ; Sawant, R; Song, Y; Tang, P; Tundia, N | 1 |
| Balsa, A; Casado, MA; de Andrés-Nogales, F; Gómez, S; Martinez-Sesmero, JM; Montoro, M; Navarro, F; Oyagüez, I; Peral, C; Valderrama, M | 1 |
| Chen, Y; Dong, P; Guo, Q; Ma, A; Tian, L; Wang, L; Xiong, X | 1 |
| Amuro, H; Ebina, K; Hara, R; Hashimoto, M; Hirano, T; Hirao, M; Jinno, S; Katayama, M; Kumanogoh, A; Maeda, Y; Murata, K; Nakata, K; Okita, Y; Onishi, A; Son, Y; Takeuchi, T; Yamamoto, K; Yamamoto, W; Yoshikawa, A | 1 |
| Lee, YH; Sung, YK | 1 |
| Fleischmann, R; Hirose, T; Iikuni, N; Paulissen, J; Shi, H; Smolen, JS; Soma, K; Takeuchi, T | 1 |
| Bensimon, A; Bergman, M; Clewell, J; Orvis, E; Tundia, N; Yang, M | 1 |
| Bessette, L; Kinch, CD; Kwok, K; Lukic, T; Mysler, E; On, PV; van Vollenhoven, RF | 1 |
| Bartlett, SJ; Bingham, CO; Cella, D; Gold, DA; Gruben, D; Murray, C; van Vollenhoven, R | 1 |
| Keystone, EC; Mokbel, A; Movahedi, M; Ojani, P; Philippopoulos, E | 1 |
| Atsumi, T; Bracher, M; Brooks, D; Davies, J; Fleischmann, RM; Goode, C; Gupta, A; McInnes, IB; Mukherjee, S; O'Shea, C; Saurigny, D; Schifano, LA; Shelton, C; Smith, JE; Strand, V; Takeuchi, T; Taylor, PC; van der Heijde, D; Wang, M; Wang, R; Watts, S; Weinblatt, ME | 1 |
| Ciurea, A; Distler, O; Frank Bertoncelj, M; Jo, H; Killeen, T; Kwok, K; Ospelt, C; Wang, L | 1 |
37 review(s) available for pyrroles and methotrexate
| Article | Year |
|---|---|
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Health Status; Humans; Janus Kinase 3; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2010 |
[Recent progress in the treatment of rheumatoid arthritis].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Denosumab; Etanercept; Humans; Immunoglobulin G; Infliximab; Interleukin-6; Methotrexate; Molecular Targeted Therapy; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; Receptors, Tumor Necrosis Factor; Reference Standards; Remission Induction; Tumor Necrosis Factor-alpha | 2012 |
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Infections; Longitudinal Studies; Male; Methotrexate; Middle Aged; Piperidines; Prevalence; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinases; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Topics: Arthritis, Rheumatoid; Humans; Inflammation; Janus Kinase 1; Janus Kinase 3; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT1 Transcription Factor; Translational Research, Biomedical; Tumor Necrosis Factor-alpha | 2015 |
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Etanercept; Humans; Infliximab; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab | 2016 |
[Guidelines for the management of rheumatoid arthritis].
Topics: Abatacept; Algorithms; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Substitution; Drug Therapy, Combination; Humans; Japan; Methotrexate; Piperidines; Practice Guidelines as Topic; Pyrimidines; Pyrroles | 2016 |
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Disease Progression; Etanercept; Humans; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure | 2016 |
New targets in psoriatic arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cyclophosphamide; Etanercept; Humans; Infliximab; Methotrexate; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Ustekinumab | 2016 |
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; Male; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2016 |
Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist.
Topics: Abatacept; Antirheumatic Agents; Contraindications; Drug Interactions; Herpes Zoster Vaccine; Humans; Immunocompromised Host; Immunogenicity, Vaccine; Influenza Vaccines; Methotrexate; Piperidines; Pneumococcal Vaccines; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatologists; Rituximab; Vaccines; Vaccines, Attenuated; Yellow Fever Vaccine | 2017 |
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Humans; Methotrexate; Neoplasms; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure | 2017 |
Medical and Maintenance Treatments for Vitiligo.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; alpha-MSH; Anti-Bacterial Agents; Calcineurin Inhibitors; Dinoprostone; Humans; Immunosuppressive Agents; Low-Level Light Therapy; Methotrexate; Minocycline; Oxytocics; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Ultraviolet Therapy; Vitamin D; Vitiligo | 2017 |
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2017 |
Influence of drug molecules on regulatory B cells.
Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B-Cell Activating Factor; B-Lymphocytes, Regulatory; CD40 Antigens; Cytokines; Humans; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Pyrroles; Quinazolines; Receptors, Antigen, B-Cell; Semaphorins; Sirolimus; Toll-Like Receptors; Tretinoin; Vitamin D; Vitamins | 2017 |
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Topics: Abatacept; Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Etanercept; Humans; Infliximab; Methotrexate; Methylprednisolone; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab | 2017 |
A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Tofacitinib: A Review in Rheumatoid Arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Janus Kinases; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2017 |
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Costs; Drug Resistance; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Technology Assessment, Biomedical | 2018 |
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Factors; Drug Therapy, Combination; Etanercept; Humans; Infliximab; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome | 2019 |
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Confidence Intervals; Humans; Infliximab; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Time Factors; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2019 |
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Tofacitinib: A Review in Psoriatic Arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Psoriatic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2019 |
Tofacitinib for the treatment of rheumatoid arthritis: an update.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2019 |
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles | 2019 |
Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
[Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2020 |
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Cost-Benefit Analysis; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Treatment Outcome | 2020 |
Comparison of the efficacy and safety of tofacitinib and mavrilimumab in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
The Proportion of Patients With Rheumatoid Arthritis Achieving ACR20/50/70; Consistent Patterns of a 60/40/20 as Demonstrated by a Systematic Review and Meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; Methotrexate; Pyrroles; Treatment Outcome | 2023 |
36 trial(s) available for pyrroles and methotrexate
| Article | Year |
|---|---|
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Blood Sedimentation; Blood Viscosity; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Methotrexate; Middle Aged; Pyrroles; Risk Factors; von Willebrand Factor | 2004 |
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2010 |
Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis.
Topics: Adiponectin; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Drug Therapy, Combination; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Methotrexate; Middle Aged; Prednisone; Pyrroles; Regional Blood Flow; Resistin; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2011 |
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunomodulation; Janus Kinase 3; Longitudinal Studies; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2011 |
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Topics: Adalimumab; Administration, Oral; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Drug Tolerance; Female; Health Status; Humans; Injections, Subcutaneous; Janus Kinase 3; Joints; Male; Methotrexate; Middle Aged; Pilot Projects; Piperidines; Pyrimidines; Pyrroles; Recovery of Function | 2012 |
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Least-Squares Analysis; Leukocyte Count; Lipoproteins; Male; Methotrexate; Middle Aged; Neutrophils; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Pain Measurement; Piperidines; Pyrimidines; Pyrroles; Recurrence; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Resistance; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Motor Activity; Piperidines; Pyrimidines; Pyrroles; Radiography; Treatment Outcome | 2013 |
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2013 |
Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; C-Reactive Protein; Double-Blind Method; Down-Regulation; Female; Humans; Interleukin-6; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Serum Amyloid A Protein | 2014 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Herpes Zoster; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Self Report; Treatment Outcome | 2015 |
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chemokines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 1; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA, Messenger; Signal Transduction; STAT Transcription Factors; Synovial Membrane; Treatment Outcome | 2015 |
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Male; Methotrexate; Middle Aged; Piperidines; Pneumococcal Infections; Pneumococcal Vaccines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2016 |
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Japan; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2016 |
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index; Treatment Outcome | 2016 |
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitati
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone Marrow; Bone Marrow Diseases; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Hand; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Synovitis; Treatment Outcome; Wrist Joint | 2016 |
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Regression Analysis; Surveys and Questionnaires; Treatment Outcome | 2017 |
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost of Illness; Double-Blind Method; Drug Therapy, Combination; Female; Health Expenditures; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Return to Work; Risk Factors; Treatment Outcome | 2017 |
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Topics: Adalimumab; Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2017 |
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Topics: Aged; Antibodies, Viral; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Enzyme-Linked Immunospot Assay; Female; Herpes Zoster; Herpes Zoster Vaccine; Herpesvirus 3, Human; Humans; Immunogenicity, Vaccine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes | 2017 |
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2018 |
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2018 |
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2018 |
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2020 |
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Piperidines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
Topics: Adalimumab; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2019 |
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
Topics: Adalimumab; Antirheumatic Agents; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Treatment Outcome; United States | 2022 |
The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sleep; Treatment Outcome | 2022 |
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Double-Blind Method; Humans; Methotrexate; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
55 other study(ies) available for pyrroles and methotrexate
| Article | Year |
|---|---|
Interference with nucleoside transport in mouse lymphoma cells proliferating in culture.
Topics: Adenosine; Animals; Ascitic Fluid; Aza Compounds; Biological Transport; Bromodeoxyuridine; Carbon Isotopes; Cell Division; Cell-Free System; Cells, Cultured; Guanosine; Inosine; Lymphoma; Male; Mercaptopurine; Methotrexate; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Pyrimidinones; Pyrroles; Ribonucleosides; Thymidine; Time Factors; Transplantation, Homologous | 1972 |
[Dermatologic topical treatment. 5. Psoriasis].
Topics: Anthracenes; Humans; Methotrexate; Ointments; Psoriasis; Pyrroles; Steroids; Ultraviolet Therapy | 1971 |
PRO-LIGAND: an approach to de novo molecular design. 3. A genetic algorithm for structure refinement.
Topics: Algorithms; Biological Evolution; Computer Graphics; Drug Design; Methotrexate; Models, Genetic; Models, Molecular; Molecular Conformation; Protein Conformation; Pyrroles; Software | 1995 |
Application of in vivo microdialysis to transdermal absorption of methotrexate in rats.
Topics: Administration, Cutaneous; Animals; Drug Carriers; Fluorescence Polarization Immunoassay; Male; Methotrexate; Microdialysis; Pyrroles; Rats; Rats, Wistar; Skin Absorption | 1994 |
Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Experimental; Azepines; Enzyme Inhibitors; Indomethacin; Lymphocyte Activation; Male; Methotrexate; Protein Kinase C; Pyrroles; Rats; Rats, Inbred Lew | 1995 |
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of N(omega)-masked ornithine analogs.
Topics: Cell Division; Drug Resistance, Neoplasm; Folic Acid Antagonists; Humans; Magnetic Resonance Spectroscopy; Methotrexate; Pyrimidines; Pyrroles; Spectrophotometry, Infrared; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured | 2000 |
A new and efficient synthesis of pyrrolo[2,3-d]pyrimidine anticancer agents: Alimta (LY231514, MTA), homo-Alimta, TNP-351, and some aryl 5-substituted pyrrolo[2,3-d]pyrimidines.
Topics: Antineoplastic Agents; Glutamates; Guanine; Methotrexate; Molecular Structure; Pemetrexed; Pyrimidines; Pyrroles | 2003 |
Rheumatoid arthritis treatment progressing.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cyclophosphamide; Drug Therapy, Combination; Heptanoic Acids; Humans; Methotrexate; Pyrroles; Rituximab | 2004 |
Progressive myopathy with up-regulation of MHC-I associated with statin therapy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atorvastatin; Creatine Kinase; Female; Folic Acid Antagonists; Genes, MHC Class I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Methotrexate; Middle Aged; Mitochondria, Muscle; Muscle Weakness; Muscular Diseases; Prednisolone; Pyrroles; Sarcolemma; Simvastatin; Up-Regulation | 2007 |
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Inhibitory Concentration 50; Methotrexate; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Sunitinib; Time Factors; Topotecan; Transfection; Up-Regulation; Vincristine | 2009 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
Serious adverse events-missing in action: comment on the article by Kremer et al.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Pyrimidines; Pyrroles | 2012 |
Kinase inhibition in rheumatoid arthritis: a big advance?
Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Statin-associated polymyositis following omeprazole treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Interactions; Esophagitis; Gemfibrozil; Heptanoic Acids; Humans; Male; Methotrexate; Middle Aged; Myocardial Infarction; Omeprazole; Polymyositis; Prednisone; Proton Pump Inhibitors; Pyrroles; Treatment Outcome; Withholding Treatment | 2013 |
Effect of atorvastatin and methotrexate on solid Ehrlich tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Atorvastatin; Carcinoma, Ehrlich Tumor; Catalase; Cholesterol; Glutathione Reductase; Heptanoic Acids; Immunohistochemistry; Male; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib for rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib for rheumatoid arthritis - Authors' reply.
Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2013 |
Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Pyrimidines; Pyrroles | 2015 |
Rheumatoid arthritis: can tofacitinib be used as first-line monotherapy for RA?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2014 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2014 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2014 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2014 |
A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2015 |
Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunomodulation; Male; Methotrexate; Pyrimidines; Pyrroles | 2016 |
New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Appendectomy; Azathioprine; Colitis, Ulcerative; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Fecal Microbiota Transplantation; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Leukapheresis; Mercaptopurine; Mesalamine; Methotrexate; New Zealand; Pediatrics; Piperidines; Proctocolectomy, Restorative; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; Tacrolimus; Tumor Necrosis Factor-alpha | 2015 |
Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes.
Topics: Antimetabolites, Antineoplastic; Cells, Cultured; Cytokines; Humans; Lymphocyte Activation; Lymphocytes; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant, Newborn; Methotrexate; Piperidines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult | 2016 |
A case of refractory dermatomyositis responsive to tofacitinib.
Topics: Azathioprine; Dermatomyositis; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methotrexate; Middle Aged; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Retreatment; Treatment Failure; Treatment Outcome | 2017 |
Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy.
Topics: Aged; Antiviral Agents; Arthritis, Rheumatoid; Cytomegalovirus Retinitis; Ganciclovir; Humans; Immunosuppressive Agents; Intravitreal Injections; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Uveitis | 2017 |
A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents.
Topics: Animals; Cyclosporine; Cytokines; Dermatitis, Atopic; Female; Haptens; Humans; Immunoglobulin E; Inflammation; Interleukin-23; Interleukin-23 Subunit p19; Janus Kinase Inhibitors; Male; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrroles; Rats; Rats, Inbred BN; Skin; Thymic Stromal Lymphopoietin | 2018 |
Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; C-Reactive Protein; CD4-Positive T-Lymphocytes; Foot; Foot Joints; Forelimb; Hindlimb; Interferon-gamma; Interleukin-1beta; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen | 2017 |
Rheumatoid arthritis: JAK-ing up inadequate RA therapy.
Topics: Adalimumab; Arthritis, Rheumatoid; Double-Blind Method; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2017 |
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Clinical Trials as Topic; Databases, Factual; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucocorticoids; Herpes Zoster; Humans; Incidence; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors | 2017 |
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol; Cohort Studies; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Single-Blind Method; Surveys and Questionnaires; Ultrasonography; Up-Regulation | 2017 |
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Ethics, Research; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Remission Induction; Research Design; Research Subjects; Time Factors; Treatment Outcome; Vulnerable Populations | 2018 |
[Current and upcoming treatments of adult atopic dermatitis].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Ustekinumab | 2017 |
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Infections; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2018 |
Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Patient Compliance; Physicians; Piperidines; Prescriptions; Pyrimidines; Pyrroles; Risk Factors | 2018 |
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Inflammation; Methotrexate; Phenotype; Piperidines; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Signal Transduction | 2018 |
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Decision-Making; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Drug Costs; Drug Substitution; Humans; Methotrexate; Models, Economic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; United States | 2018 |
Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib.
Topics: Acquired Hyperostosis Syndrome; Adult; Antirheumatic Agents; Autoimmunity; Bone and Bones; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Immunologic Tests; Janus Kinase Inhibitors; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Tomography, Emission-Computed; Treatment Outcome | 2018 |
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Topics: Aged; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Herpes Zoster; Humans; Incidence; Janus Kinase Inhibitors; Male; Medicare; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Pyrimidines; Pyrroles; Risk Assessment; Time Factors; United States | 2019 |
A novel mixed hemimicelles dispersive micro-solid phase extraction using ionic liquid functionalized magnetic graphene oxide/polypyrrole for extraction and pre-concentration of methotrexate from urine samples followed by the spectrophotometric method.
Topics: Graphite; Humans; Hydrogen-Ion Concentration; Ionic Liquids; Magnetic Phenomena; Methotrexate; Models, Molecular; Molecular Structure; Nanocomposites; Polymers; Pyrroles; Solid Phase Microextraction; Spectrophotometry; X-Ray Diffraction | 2019 |
2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Decision Making; Drug Substitution; Drug Therapy, Combination; Glucocorticoids; Humans; Hydroxychloroquine; Leflunomide; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Societies, Medical; Sulfasalazine | 2018 |
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Topics: Adalimumab; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Cost-Benefit Analysis; Etanercept; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2019 |
Breastfeeding with Inflammatory Bowel Disease.
Topics: Aminosalicylic Acid; Biological Products; Breast Feeding; Female; Humans; Inflammatory Bowel Diseases; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2019 |
NIR- and thermo-responsive semi-interpenetrated polypyrrole nanogels for imaging guided combinational photothermal and chemotherapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Contrast Media; Diagnostic Imaging; Drug Delivery Systems; Female; Hot Temperature; Humans; Methotrexate; Mice, Nude; Nanogels; Neoplasms; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles | 2019 |
Methotrexate-Induced Pneumonitis in Rheumatoid Arthritis: Long-term Treatment With Tofacitinib Therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pneumonia; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2020 |
Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.
Topics: Adult; Ambulatory Care; Biological Products; Clinical Decision-Making; Colitis, Ulcerative; Decision Support Techniques; Drug Therapy, Combination; Humans; Immunologic Factors; Methotrexate; Piperidines; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Severity of Illness Index | 2020 |
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Spain; Treatment Outcome | 2020 |
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cohort Studies; Female; Humans; Methotrexate; Middle Aged; Pharmaceutical Preparations; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Pyrroles; Treatment Outcome | 2023 |